depression with semaglutide and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database Does Semaglutide Cause Depression? Mood

Kimball CP, Murlin JR (1923) Aqueous extracts of pancreas: III

Its essential that you are open and transparent about your health conditions and any medications or supplements you are taking to ensure the best possible outcomes and minimize potential risks

Lau J, Bloch P, Schaffer L, Pettersson I, Spetzler J, Kofoed J, et al

In summary, the therapeutic rationale for dual GLP-1/GIP receptor agonists in the treatment of obesity and Type 2 Diabetes is to harness and enhance the physiological roles of these incretins in glucose regulation and weight management, while optimizing the drug's signaling to improve efficacy, duration of action, and tolerability.The science underpinning the use of GLP-1 and GIP receptor agonists in the treatment of obesity and type 2 diabetes (T2D) is well-established, but some aspects are still subject to ongoing research and debate